Suchergebnisse - "Hanauer, Stephen B"

PubPharm (9)

1

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases : recommendations from an international consensus meeting

enthalten in: Gut | 2021

von Siegel, C. | Melmed, G. | McGovern, D. | +68

2

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab : a retrospective analysis of the ACCENT I trial

enthalten in: Gut | 2014

von Cornillie, F. | Hanauer, S. | Diamond, R. | +5

3

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

enthalten in: Gut | 2014

von Cornillie, F. | Hanauer, S. | Diamond, R. | +5

4

In memoriam : Dr Joseph Barnett Kirsner

enthalten in: Gut | 2012

von Hanauer, S. | Rubin, D. | Kirsner, J.

5

In memoriam: Dr Joseph Barnett Kirsner

enthalten in: Gut | 2012

von Hanauer, S. | Rubin, D.

6

Developing an instrument to assess the endoscopic severity of ulcerative colitis : the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

enthalten in: Gut | 2012

von Travis, S. | Schnell, D. | Krzeski, P. | +14

CommentIn: Endoscopy. 2013;45(4):289-91. - PMID 23468192

7

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

enthalten in: Gut | 2012

von Travis, S. | Schnell, D. | Krzeski, P. | +14

8

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease : is the synergy worth the risk?

enthalten in: Gut | 2007

von Hanauer, S.

CommentOn: Gut. 2007 Sep;56(9):1226-31. - PMID 17229796

9

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

enthalten in: Gut | 2007

von Hanauer, S.

1
[1]